Report: Endo to shutter R&D facility; Prosensa's DMD drugs earn orphan status; Zytoprotec raises 2M euros;

 @FierceBiotech: Genentech plucks rights to Afraxis drug assets in $187M deal. News | Follow @FierceBiotech

@JohnCFierce: Big Biotech throwing up state legislative roadblocks against biosimilars, from Pollack at the NYT. More | Follow @JohnCFierce

@RyanMFierce: Biotech billionaire Soon-Shiong unveils 'convergence' cancer drug startup... Why it's unique? Tech convergence. News | Follow @RyanMFierce

> Pharmalot reports that Endo--which sells the painkiller Opana--is closing an R&D facility in Long Island, axing 58 workers in the process. Story

> The Dutch biotech Prosensa won orphan drug status for all its Duchenne muscular dystrophy drugs in the U.S. and Europe. Release

> Austria's Zytoprotec raised €2 million from new investor Baxter Ventures, half of a planned €4 million Series A. Release

> Alnylam CEO John Maraganore says all of the company's $400 million in cash will be needed to back its pipeline efforts, with no plans to make an acquisition. Story

> Bausch + Lomb launched its Phase III program for latanoprostene bunod (previously known as BOL-303259-X and NCX 116, in-licensed from NicOx) for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. Release

Pharma News

@FiercePharma: Another Hospira recall: Electrolyte solution, after customer complained of mold. No reported injuries. More | Follow @FiercePharma

 @AlisonBFierce: DARPA produced 10 million H1N1 flu vaccine doses in a month. DARPA, Medicago are using tobacco plants instead of eggs. News | Follow @AlisonBFierce

@EricPFierce: Sartorius Stedim nabs top LEED designation for Puerto Rico plant that recycles AC condensation, uses solar power. Article | Follow @EricPFierce

> Fighting the $9B ghost of Lipitor past, Pfizer points to new drugs. Report

> Lilly sales and profits slide, but analysts expected worse. Article

Medical Device News

 @FierceMedDev: Medtronic launches large-scale neurostimulation trial. Item | Follow @FierceMedDev

 @MarkHFierce: BSX will cut as many as 1,000 additional jobs beyond 2011 restructuring--first disclosed in today's Q4 announcement. Release | Follow @MarkHFierce

 @DamianFierce: Next in the Bausch + Lomb saga: Either it's going for an IPO or this is a gambit to pressure buyers. News | Follow @DamianFierce

> Illumina soars on deCode sale, revenue jump. Report

> Blood Dx quickens search for breast cancer mutations. Story

Pharma Manufacturing News

> Hospira recalls product that may contain mold. News

> EU drugmakers say expect a year from OK to warehouse for new labels. Item

> FDA alleges 3 made millions off scam wholesaler. Story

> Sartorius PR plant first to get LEED's top rating. Article

Biotech Research News

> Addex approaches the clinic for rare dystonias. Article

> Orexo, AstraZeneca join forces against respiratory disease. Item

> Beta blockers could improve cancer treatment in stressed patients. News

> Stem cells help rats recover from stroke. Story

And Finally… A new Kaiser Permanente study finds that HIV patients suffer a higher rate of nonmelanoma skin cancer. Release

 

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.